NCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
Clinical Trials
26 trialsNCT04334759 2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3 Completed
NCT02060188 2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2 Completed
NCT03195478 2025-09-15
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT04040231 2025-05-13
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02913313 2025-04-20
A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03063450 2025-04-10
CONFIRM
University of Southampton
Phase 3 Completed
NCT01928394 2024-12-27
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02899299 2024-05-21
CheckMate743
Bristol-Myers Squibb
Phase 3 Completed
NCT04887194 2024-05-08
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Mirati Therapeutics Inc.
Phase 1 Completed
NCT02261285 2024-05-06
ONO-4538 Phase I Study in Patients With Solid Tumor
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT03728179 2024-02-20
RACIN
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT05498480 2024-02-20
RELATIVITY-111
Bristol-Myers Squibb
Phase 1 Completed
NCT05041062 2024-01-03
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago
Phase 2 Completed
NCT03730337 2023-10-04
Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT02426892 2023-04-18
Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02598960 2023-03-06
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02593786 2022-10-24
CheckMate 077
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02716272 2021-02-10
MAPS2
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT03048474 2021-01-20
INITIATE
The Netherlands Cancer Institute
Phase 2 Completed
NCT00836888 2020-10-08
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT02614456 2019-11-29
Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
Fox Chase Cancer Center
Phase 1 Completed
NCT02476123 2019-06-11
Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT02497508 2017-09-14
NivoMes
The Netherlands Cancer Institute
Phase 2 Completed